| Assessment Status | Rapid Review complete |
| HTA ID | 22056 |
| Drug | Buprenorphine |
| Brand | Buvidal® |
| Indication | Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. |
| Assessment Process | |
| Rapid review commissioned | 09/08/2022 |
| Rapid review completed | 23/09/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Buvidal® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
